It's time to change drug development.

It's why we invented
Targeted Drug Carriers.

Instead of flooding the entire body with toxic drugs, we've created a delivery system that acts like a guided missile, seeking out and destroying only cancer cells.

We call them Targeted Drug Carriers or TDCs, and they have the potential to transform hard to treat solid cancers from a death sentence into a manageable condition.

Breakthrough outcomes require breakthrough innovation.

A novel therapeutic modality.

Inspired by small molecule ligands for incredibly small therapeutics.

A proprietary platform to generate novel drugs that actually accumulate in targeted tissues, with an ability to administer small doses with superb efficacy and safety.

A novel therapeutic modality.

Inspired by small molecule ligands for incredibly small therapeutics.

A proprietary platform to generate novel drugs that actually accumulate in targeted tissues, with an ability to administer small doses with superb efficacy and safety.

A novel therapeutic modality.

Inspired by small molecule ligands for incredibly small therapeutics.

A proprietary platform to generate novel drugs that actually accumulate in targeted tissues, with an ability to administer small doses with superb efficacy and safety.

Utilizing the best of science.

All the strengths and none of the failings of current treatment platforms.

Our TDCs latch onto tumors and have a long half-life allowing them to substantially accumulate in a tumor. Once inside the tumor, they release a powerful drug that destroys it.

Utilizing the best of science.

All the strengths and none of the failings of current treatment platforms.

Our TDCs latch onto tumors and have a long half-life allowing them to substantially accumulate in a tumor. Once inside the tumor, they release a powerful drug that destroys it.

Utilizing the best of science.

All the strengths and none of the failings of current treatment platforms.

Our TDCs latch onto tumors and have a long half-life allowing them to substantially accumulate in a tumor. Once inside the tumor, they release a powerful drug that destroys it.

Addressing huge unmet need.

We're tackling some of the most challenging cancers faced by patients.

Tumors that are especially dense have remained elusive to treatment. It's why we are developing drugs specifically for them, such as colorectal, gynecological, pancreatic and prostate cancers.

Addressing huge unmet need.

We're tackling some of the most challenging cancers faced by patients.

Tumors that are especially dense have remained elusive to treatment. It's why we are developing drugs specifically for them, such as colorectal, gynecological, pancreatic and prostate cancers.

Addressing huge unmet need.

We're tackling some of the most challenging cancers faced by patients.

Tumors that are especially dense have remained elusive to treatment. It's why we are developing drugs specifically for them, such as colorectal, gynecological, pancreatic and prostate cancers.

It's time to change drug development.

It's why we inventedTargeted Drug Carriers.

Breakthrough outcomes require breakthrough innovation.

Inspired by small molecule ligands for incredibly small therapeutics.

Inspired by small molecule ligands for incredibly small therapeutics.

Inspired by small molecule ligands for incredibly small therapeutics.

All the strengths and none of the failings of current treatment platforms.

All the strengths and none of the failings of current treatment platforms.

All the strengths and none of the failings of current treatment platforms.

We're tackling some of the most challenging cancers faced by patients.

We're tackling some of the most challenging cancers faced by patients.

We're tackling some of the most challenging cancers faced by patients.

It's why we invented
Targeted Drug Carriers.